Modify risk rather than merely relying on blood sugar lowering drugs in diabetes: DECLARE-TIMI Medha Baranwal Baranwal27 Sept 2019 7:28 PM ISTModify risk rather than merely relying on blood sugar lowering drugs in diabetes, finds DECLARE-TIMI Phase IIIB trial.Researchers, based on their...
FDA approves Dapagliflozin to reduce risk of Heart Failure in Diabetes Dr. Kamal Kant Kohli Kohli23 Oct 2019 7:20 PM ISTFood and Drug Administration has approved Dapagliflozin to reduce the risk for Heart Failure Hospitalization in Diabetes.The US Food and Drug...
Top Cardiology News: 2019 Medha Baranwal Baranwal29 Dec 2019 8:28 PM ISTThe year 2019 witnessed another active year for research and clinical advances in the field of cardiology. New drugs, devices, diagnoses, prognoses...
SGLT2 inhibitors reduce risk of heart attack and death: BMJ Deepanjana Sarkar2 Sept 2019 8:28 PM ISTBlood sugar lowering agents SGLT2 inhibitors lower risk of heart attack and death finds a new study.Type 2 diabetes drug, sodium-glucose transport...
Dapagliflozin reduces hospitalisation and CV death risk in heart failure patients: Dapa-HF clinical trial Dr. Kamal Kant Kohli Kohli21 Aug 2019 8:20 PM ISTDapagliflozin an SGLT2 inhibitor reduces hospitalization and CV death risk in heart failure patients with or without diabetes, finds Dapa-HF clinical...
SGLT2 inhibitors do not increase bladder cancer risk, contrary to concerns raised Medha Baranwal Baranwal28 July 2019 7:25 PM ISTFlorence, Italy: Widely used medications for type 2 diabetes, SGLT‐2 inhibitors, do not increase the risk of cancer in general or, bladder cancer in...
Should cardiologists prescribe SGLT2 Inhibitor routinely to all Medha Baranwal Baranwal11 April 2019 7:03 PM ISTSGLT2 inhibitors are introduced primarily as glucose-lowering drugs but the new analysis of DECLARE-TIMI 58 trial gave startling revelations that...
PERSPECTIVE: Diabetes management with SGLT2 inhibitors changing directions- Dr Anoop Misra, Dr Amrita Ghosh Deepanjana Sarkar31 March 2019 8:28 PM ISTThere have been remarkable changes in the treatment of type 2 diabetes during the last decade. Focus has shifted from older class of drug (except...
